✦ LIBER ✦

ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non–Small-Cell Lung Cancer?

✍ Scribed by Toyokawa, Gouji; Seto, Takashi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug-induced reduction in estimated glom

✍ Brosnan, Evelyn M.; Weickhardt, Andrew J.; Lu, Xian; Maxon, Delee A.; Barón, Ann 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 520 KB

Overcoming the resistance to Crizotinib

✍ Perez, Cesar A.; Velez, Michel; Raez, Luis E.; Santos, Edgardo S. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 868 KB

210 EML4-ALK is a sensitive client prote

✍ C. Fritz; A. Lim; K. Slocum; C. Tunkey; G. Paez; K. West; R. Ross; E. Normant; L 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

369 Timing of responses to crizotinib (P

✍ B. Solomon; Y.J. Bang; D.R. Camidge; A.J. Iafrate; E.L. Kwak; R.G. Maki; S.I. Ou 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Activity and safety of crizotinib in pat

✍ D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella- 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 310 KB

Effect of crizotinib on overall survival

✍ Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; J 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 250 KB